Axa Framlington Biotech Fund

Select share classes

AXA Framlington Biotech Fund Z INC

Category Sector Equity Biotechnology


star-filledstar-filledstar-filledstar-filled
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price

160.60p

arrow-down-2.30p (-1.41%)

Fund Code

FMBZI

BRJZVL2

GB00BRJZVL27

Prices updated as at 02 May 2025
|
Prices in GBX

Investment objective
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.

Annual performance (%)

YearThis fundSector Equity Biotechnology
31 Mar 14 - 31 Mar 1572.8450.17
31 Mar 15 - 31 Mar 16-26.70-22.76
31 Mar 16 - 31 Mar 1730.5832.54
31 Mar 17 - 31 Mar 180.37-2.35
31 Mar 18 - 31 Mar 1910.428.06
31 Mar 19 - 31 Mar 203.12-0.43
31 Mar 20 - 31 Mar 2124.0225.77
31 Mar 21 - 31 Mar 220.66-15.21
31 Mar 22 - 31 Mar 239.16-3.25
31 Mar 23 - 31 Mar 2410.855.53
31 Mar 24 - 31 Mar 25-10.38-11.07

Trailing returns (%)

YearThis fundSector Equity Biotechnology
1 Day-1.411.62
1 Month1.202.34
3 Months-14.30-11.35
6 Months-14.67-10.96
1 Year-8.91-7.30
3 Years annualised2.991.99
5 Years annualised3.350.92
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.


Any ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
© Copyright 2025 Morningstar. All rights reserved.